Hemogenyx Pharmaceuticals Plc
HEMO.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £13,371 | £25,970 | £13,031 | £14,550 |
| - Cash | £159 | £1,248 | £2,533 | £6,841 |
| + Debt | £2,623 | £2,946 | £3,423 | £10 |
| Enterprise Value | £15,835 | £27,668 | £13,921 | £7,719 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | – | – | – |
| Gross Profit | -£639 | -£646 | -£2,600 | -£284 |
| % Margin | – | – | – | – |
| EBITDA | -£4,715 | -£5,735 | -£3,423 | -£2,387 |
| % Margin | – | – | – | – |
| Net Income | -£5,619 | -£6,691 | -£3,979 | -£5,099 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.7 | -2.37 | -1.62 | -2.64 |
| % Growth | 28.3% | -46.3% | 38.6% | – |
| Operating Cash Flow | -£4,117 | -£6,106 | -£2,911 | -£2,627 |
| Capital Expenditures | -£13 | -£117 | -£429 | -£818 |
| Free Cash Flow | -£4,130 | -£6,223 | -£3,340 | -£3,445 |